Openbookopenbook
Equity
Eterna Therapeutics Inc(ERNA)
USD --+0.00%
Reward34Low
Risk79High
📊75%Data
Revenue down 94% YoY
ERNA
+0.0 · +0.00%
USD · NASDAQ
Eterna Therapeutics Inc | Healthcare
Earnings Deterioration
Market Cap:8.13M
ℹ️
Reward Rating
34
Low
Bottom 5% (model universe)
75% data coverage
ℹ️
Risk Rating
79
High
Risk Assessment
ℹ️

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

ℹ️ Educational tool only · More
Limited data coverage
We don't have enough public data on ERNA to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available for limited-coverage stocks
The overview tab requires fundamentals and price history we don't have for this stock. The price chart is the most reliable view we have — try the Chart tab.

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

Analyst Target

Analyst consensus price target: $3.00.

What is Eterna Therapeutics Inc?

, a preclinical-stage company, develops induces derived mesenchymal stem cells (iMSC) therapies for the treatment of solid tumors and autoimmune disease.

ERNA · Verdict

Limited reward · high risk

ERNA has limited near-term tailwinds — volatility and cash flow weigh on the model output.

Based on 88% data coverage

ERNA · Verdict

What’s working & what to watch

Watchouts 4

  • Volatility5/100

    Weak vs peers

  • Cash flow6/100

    -2784% free-cash-flow margin

  • Growth18/100

    Earnings -28.6% CAGR

  • Profitability32/100

    -7653% net margin · -2264% ROE

Model-based scoring. For information only — not financial advice.

What is Eterna Therapeutics Inc?

, a preclinical-stage company, develops induces derived mesenchymal stem cells (iMSC) therapies for the treatment of solid tumors and autoimmune disease. The company's lead product is ERNA-101, an allogenic pro-inflammatory cytokine (IL-7/IL-15) secreting iMSC for the treatment of ovarian cancer; and ERNA-102, an anti-inflammatory cytokine (IL-10) secreting iMSC for the treatment of rheumatoid arthritis. The company is listed on the NASDAQ in USA, operating in the Healthcare sector, with a market capitalisation of 8.13M.

Financial Highlights

Investment Breakdown

📈 Growth
Revenue growth is subdued, limiting near-term earnings expansion.
💰 Profitability
Thin or inconsistent margins weigh on earnings quality.
⚠️ Risk
Elevated volatility implies higher downside and expectation risk.
💸 Valuation
Valuation appears fair relative to current fundamentals.

OpenBook Logo Analysis

Reward: Low (34)

The scoring profile indicates weak reward characteristics across most factors, including valuation and momentum. Risk indicators are high — this profile reflects meaningful downside exposure.

For informational purposes only. Not financial advice.

Company Information
SectorHealthcare
Market Cap8.13M
P/E Ratio0.0053
Dividend YieldN/A
52 Week High4.5
52 Week Low0.27
Last AnnualDecember
IPO Date10/19/1992
IncorporatedUSA
Shares Outstanding27M
No. of Employees6
IndustryBiotechnology
ExchangeNASDAQ
Beta6.737
CurrencyUSD
Websitewww.ernexatx.com
openbook

Stock research for everyday UK investors. Make smarter decisions, faster.

Questions? Email us at contact@openbookanalytics.com

© 2026 Openbook Analytics Ltd · Company No. SC843579 · Registered in Scotland

256-bit encryption GDPR compliant UK data centres

Openbook Analytics Ltd (Company No. SC843579) is registered in Scotland. Registered office: Strathclyde Inspire Hub, University of Strathclyde, Graham Hills Building (Level 6), 50 Richmond Street, Glasgow, G1 1XP. Openbook Analytics is not authorised or regulated by the Financial Conduct Authority (FCA). The content on this platform is provided for general informational and educational purposes only and does not constitute financial advice, investment advice, trading advice, or any other form of advice. You should not treat any content on this platform as a recommendation to buy, sell, or hold any financial instrument. Past performance is not a reliable indicator of future results. The value of investments and the income from them can go down as well as up, and you may get back less than you invest. User-generated content, including community posts and commentary, reflects the personal opinions of individual users, is not verified for accuracy, and does not represent the views of Openbook Analytics Ltd. You should always conduct your own research or consult a qualified, FCA-regulated financial adviser before making investment decisions. Data displayed on this platform may be delayed or inaccurate and is provided "as is" without warranty. Openbook Analytics Ltd accepts no liability for any loss arising from reliance on the information provided.